PillRx only · Injection, Solution · Subcutaneous
Tralokinumab-Ldrm
Brands: Adbry · Tralokinumab
1 ACTIVE SUPPLIER — US
openFDA · updated weekly
US2 NDCs
1 active makers
1 active makers
UKComing
soon
soon
CAComing
soon
soon
AUComing
soon
soon
EUComing
soon
soon
Medicaid dispensing volumeSDUD · per quarter
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.
9.5K
Rx · 2026 Q1
35K
Units dispensed
+10%
Rx vs. year ago
5
Quarters · since 2025 Q1
Who makes it1 active · 0 exited
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| LEO Pharma Inc. | unknown | 6 | SUPPLYING |
Regulatory & supply eventsFDA · US
Shortages, recalls, and registration changes attached to this drug concept.
- Feb 10, 2026RECALLRecall (Class II): Adbry, (tralokinumab-ldrm) injection, 300 mg/2mL, Packaged as a) 1 x Single dose Autoinjector, SAMPLE NOT FOR SALE, NDC…
Lack of Assurance of Sterility: due to the presence of particulate matter in one unit from the lot, which lab tests have identified as wool fiber. — Recalling firm: LEO PHARMA INC — Nationwide in the USA